Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir

Clin Infect Dis. 2016 Aug 15;63(4):528-31. doi: 10.1093/cid/ciw349. Epub 2016 May 25.

Abstract

We assessed the efficacy and safety of ledipasvir/sofosbuvir plus ribavirin for 24 weeks in 9 human immunodeficiency virus/hepatitis C virus-coinfected patients who relapsed after receiving 12 weeks of treatment with ledipasvir/sofosbuvir. Eight of 9 (89%) achieved sustained virologic response 12 weeks after the end of treatment. One patient relapsed at posttreatment week 4. These results suggest an effective salvage therapy for patients for whom direct-acting antiviral treatment has failed.

Clinical trials registration: NCT02073656.

Keywords: HCV NS5B polymerase inhibitor; HCV/HIV coinfection; NS5A resistance; direct-acting antiviral agents; re-treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antiviral Agents / therapeutic use*
  • Benzimidazoles / therapeutic use
  • Coinfection*
  • Drug Therapy, Combination
  • Fluorenes / therapeutic use
  • HIV / drug effects
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • Hepacivirus / drug effects
  • Hepatitis C, Chronic / complications
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Middle Aged
  • Recurrence
  • Ribavirin / therapeutic use*
  • Salvage Therapy
  • Sofosbuvir / therapeutic use
  • Treatment Failure

Substances

  • Antiviral Agents
  • Benzimidazoles
  • Fluorenes
  • ledipasvir
  • Ribavirin
  • Sofosbuvir

Associated data

  • ClinicalTrials.gov/NCT02073656